These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23740920)

  • 1. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
    Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
    Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine.
    Pattyn J; Panicker G; Willhauck-Fleckenstein M; Van Keer S; Téblick L; Pieters Z; Tjalma WAA; Matheeussen V; Van Damme P; Waterboer T; Unger ER; Vorsters A
    J Med Virol; 2020 Dec; 92(12):3774-3783. PubMed ID: 32266996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
    Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
    Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
    Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine.
    Azimi A; Heidarian S; Zamani H; Taleghani N; Dehghani M; Seyedjafari E
    Biologicals; 2020 Nov; 68():60-64. PubMed ID: 32859464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.
    Panicker G; Rajbhandari I; Gurbaxani BM; Querec TD; Unger ER
    J Immunol Methods; 2015 Feb; 417():107-114. PubMed ID: 25554636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
    Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
    Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
    Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
    BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix.
    Ferreira Costa AP; Gonçalves AK; Machado PRL; Souza LBFC; Sarmento A; Cobucci RNO; Giraldo PC; Witkin SS
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2313-2317. PubMed ID: 30141308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplexed serologic assay for nine anogenital human papillomavirus types.
    Opalka D; Matys K; Bojczuk P; Green T; Gesser R; Saah A; Haupt R; Dutko F; Esser MT
    Clin Vaccine Immunol; 2010 May; 17(5):818-27. PubMed ID: 20237197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.
    Mikolajczyk RT; Horn J; Damm O; Kaufmann AM; Kretzschmar ME
    J Natl Cancer Inst; 2012 Jan; 104(2):163; author reply 163-4. PubMed ID: 22232131
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.